Galantamine increases hippocampal insulin-like growth factor 2 expression via α7 nicotinic acetylcholine receptors in mice

Psychopharmacology

Volumn 225, Issue 3, 2013, Pages 543-551

  Kita, Yuki ^a   Ago, Yukio ^a   Takano, Erika ^a   Fukada, Asako ^a   Takuma, Kazuhiro ^a   Matsuda, Toshio ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Galantamine; Hippocampus; Insulin like growth factor 2 (IGF2); Neurotrophic growth factors; Nicotinic acetylcholine (ACh) receptor; Prefrontal cortex

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BUNGAROTOXIN RECEPTOR; DONEPEZIL; FIBROBLAST GROWTH FACTOR 2; GALANTAMINE; MECAMYLAMINE; MESSENGER RNA; METHYLLYCACONITINE; MUSCARINIC M1 RECEPTOR; N (3 QUINUCLIDINYL)FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; SOMATOMEDIN B; TELENZEPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; GALANTAMINE; HIPPOCAMPUS; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE; MICE, INBRED STRAINS; NEUROPROTECTIVE AGENTS; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PREFRONTAL CORTEX; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, NICOTINIC; TIME FACTORS;

EID: 84873743958     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2841-7     Document Type: Article

References (48)

1. Agis-Balboa RC, Arcos-Diaz D, Wittnam J, Govindarajan N, Blom K, Burkhardt S, Haladyniak U, Agbemenyah HY, Zovoilis A, Salinas-Riester G, Opitz L, Sananbenesi F, Fischer A (2011) A hippocampal insulin-growth factor 2 pathway regulates the extinction of fear memories. EMBO J 30:4071-4083
2. Ago Y, Koda K, Takuma K, Matsuda T (2011) Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci 116:6-17
3. Ago Y, Tanaka T, Kita Y, Tokumoto H, Takuma K, Matsuda T (2012) Lithium attenuates methamphetamine-induced hyperlocomotion and behavioral sensitization via modulation of prefrontal monoamine release. Neuropharmacology 62:1634-1639
4. Anderson MF, Aberg MA, Nilsson M, Eriksson PS (2002) Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Brain Res Dev Brain Res 134:115-122
5. Autio H, Mätlik K, Rantamäki T, Lindemann L, Hoener MC, Chao M, Arumäe U, Castrén E (2011) Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus. Neuropharmacology 61:1291-1296
6. Belluardo N, Blum M, Mudo G, Andbjer B, Fuxe K (1998) Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat. Neuroscience 83:723-740
7. Belluardo N, Mudò G, Blum M, Cheng Q, Caniglia G, Dell'Albani P, Fuxe K (1999) The nicotinic acetylcholine receptor agonist (±)- epibatidine increases FGF-2 mRNA and protein levels in the rat brain. Brain Res Mol Brain Res 74:98-110
8. Bracko O, Singer T, Aigner S, Knobloch M, Winner B, Ray J, Clemenson GD Jr, Suh H, Couillard-Despres S, Aigner L, Gage FH, Jessberger S (2012) Gene expression profiling of neural stem cells and their neuronal progeny reveals IGF2 as a regulator of adult hippocampal neurogenesis. J Neurosci 32:3376-3387
9. Brown J, Jones EY, Forbes BE (2009) Keeping IGF-II under control: lessons from the IGF-II-IGF2R crystal structure. Trends Biochem Sci 34:612-619
10. Cao L, Jiao X, Zuzga DS, Liu Y, Fong DM, Young D, During MJ (2004) VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 36:827-835
11. Chao W, D'Amore PA (2008) IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 19:111-120
12. Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebori B, Pollonini G, Bambah-Mukku D, Blitzer RD, Alberini CM (2011) A critical role for IGF-II in memory consolidation and enhancement. Nature 469:491-497
13. Constância M, Hemberger M, Hughes J, Dean W, Ferguson-Smith A, Fundele R, Stewart F, Kelsey G, Fowden A, Sibley C, Reik W (2002) Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature 417:945-948
14. Csernansky JG, Martin M, Shah R, Bertchume A, Colvin J, Dong H (2005) Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmacology 30:2135-2143
15. 2+ signals and neurotransmitter release. Mol Pharmacol 64:1217-1226
16. 1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats. Int J Neuropsychopharmacol 10:383-399
17. Frielingsdorf H, Simpson DR, Thal LJ, Pizzo DP (2007) Nerve growth factor promotes survival of new neurons in the adult hippocampus. Neurobiol Dis 26:47-55
18. Gicquel C, Le Bouc Y (2006) Hormonal regulation of fetal growth. Horm Res 65(Suppl 3):28-33
19. Gil-Bea FJ, Solas M, Mateos L, Winblad B, Ramírez MJ, Cedazo-Mínguez A (2011) Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation. Hippocampus 21:999-1009
20. Jensen AA, Mikkelsen I, Frølund B, Bräuner-Osborne EF, Krogsgaard-Larsen P (2003) Carbamoylcholine homologs: novel and potent agonists at neuronal nicotinic acetylcholine receptors. Mol Pharmacol 64:865-875
21. Jin K, Xie L, Mao XO, Greenberg DA (2006) Alzheimer's disease drugs promote neurogenesis. Brain Res 1085:183-188
22. Kataoka S, Takuma K, Hara Y, Maeda Y, Ago Y, Matsuda T (2011) Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid. Int J Neuropsychopharmacol Nov. 18:1-13 PMID: 22093185
23. Kenny PJ, File SE, Rattray M (2000) Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Brain Res Mol Brain Res 85:234-238
24. Kihara T, Sawada H, Nakamizo T, Kanki R, Yamashita H, Maelicke A, Shimohama S (2004) Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity. Biochem Biophys Res Commun 325:976-982
25. Koda K, Ago Y, Kawasaki T, Hashimoto H, Baba A, Matsuda T (2008) Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology Berl 196:293-301
26. Koda K, Ago Y, Yano K, Nishimura M, Kobayashi H, Fukada A, Takuma K, Matsuda T (2011) Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation. Br J Pharmacol 162:763-772
27. Lee J, Duan W, Mattson MP (2002) Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem 82:1367-1375
28. Lehtinen MK, Zappaterra MW, Chen X, Yang YJ, Hill AD, Lun M, Maynard T, Gonzalez D, Kim S, Ye P, D'Ercole AJ, Wong ET, LaMantia AS, Walsh CA (2011) The cerebrospinal fluid provides a proliferative niche for neural progenitor cells. Neuron 69:893-905
29. Llorens-Martín M, Torres-Alemán I, Trejo JL (2009) Mechanisms mediating brain plasticity: IGF1 and adult hippocampal neurogenesis. Neuroscientist 15:134-148
30. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX (2000) Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 113:199-206
31. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, Zerlin M (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 49:279-288
32. Mudo G, Belluardo N, Fuxe K (2007) Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm 114:135-147
33. Noda Y, Mouri A, Ando Y, Waki Y, Yamada SN, Yoshimi A, Yamada K, Ozaki N, Wang D, Nabeshima T (2010) Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. Int J Neuropsychopharmacol 13:1343-1354
34. Rossi C, Angelucci A, Costantin L, Braschi C, Mazzantini M, Babbini F, Fabbri ME, Tessarollo L, Maffei L, Berardi N, Caleo M (2006) Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. Eur J Neurosci 24:1850-1856
35. Samochocki M, Höffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lübbert H, Albuquerque EX, Maelicke A (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024-1036
36. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, Albuquerque EX (2002) The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61:1222-1234
37. Schänzer A, Wachs FP, Wilhelm D, Acker T, Cooper-Kuhn C, Beck H, Winkler J, Aigner L, Plate KH, Kuhn HG (2004) Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol 14:237-248
38. Schilström B, Ivanov VB, Wiker C, Svensson TH (2007) Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 32:43-53
39. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49:1-6
40. Sharp BM, Yatsula M, Fu Y (2004) Effects of galantamine, a nicotinic allosteric potentiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats. J Pharmacol Exp Ther 309:1116-1123
41. Sobrado M, Roda JM, López MG, Egea J, García AG (2004) Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci Lett 365:132-136
42. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A (2006) Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51:474-486
43. Tanaka K, Yagi T, Shimakoshi R, Azuma K, Nanba T, Ogo H, Tamura A, Asanuma M (2009) Effects of galantamine on L-NAME-induced behavioral impairment in Y-maze task in mice. Neurosci Lett 462:235-238
44. Villarroya M, García AG, Marco-Contelles J, López MG (2007) An update on the pharmacology of galantamine. Expert Opin Investig Drugs 16:1987-1998
45. Wadenberg ML, Fjällström AK, Federley M, Persson P, Stenqvist P (2011) Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor. Int J Neuropsychopharmacol 14:644-654
46. 25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32:1261-1271
47. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN (2006) Discovery of N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure-activity relationship. J Med Chem 49:4425-4436
48. Yano K, Koda K, Ago Y, Kobayashi H, Kawasaki T, Takuma K, Matsuda T (2009) Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice. Br J Pharmacol 156:173-180